These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38822164)

  • 1. Clinical implications for the association of psoriasis and multiple sclerosis: an observational study.
    Miele G; Sparaco M; Maida E; Bile F; Lavorgna L; Bonavita S; Ruocco E
    Neurol Sci; 2024 Nov; 45(11):5395-5403. PubMed ID: 38822164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern.
    Pinter A; Sarlak M; Zeiner KN; Malisiewicz B; Kaufmann R; Romanelli M; Koenig A; Chiricozzi A
    Dermatology; 2021; 237(5):759-768. PubMed ID: 33326954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis.
    Feldman SR; Zhao Y; Shi L; Tran MH
    J Manag Care Spec Pharm; 2015 Oct; 21(10):874-88. PubMed ID: 26402388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Burden of Concomitant Joint Disease in Psoriasis: A US-Linked Claims and Electronic Health Records Database Analysis.
    Skornicki M; Prince P; Suruki R; Lee E; Louder A
    Adv Ther; 2021 May; 38(5):2458-2471. PubMed ID: 33818686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study.
    Daudén E; Herrera E; Puig L; Sánchez-Carazo JL; Toribio J; Perulero N
    Actas Dermosifiliogr; 2013 Oct; 104(8):685-93. PubMed ID: 23958428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis as a comorbidity of hidradenitis suppurativa.
    Kjaersgaard Andersen R; Saunte SK; Jemec GBE; Saunte DM
    Int J Dermatol; 2020 Feb; 59(2):216-220. PubMed ID: 31591714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pso-Reg: a web registry for psoriasis in real life.
    Trovato E; Cartocci A; Calabrese L; D'Onghia M; Dragotto M; Capalbo E; Silvi G; Manzo Margiotta F; Pimpinelli N; Pellegrino M; Romanelli M; Dini V; Cuccia A; Mazzatenta C; Rubegni P; Prignano F
    Ital J Dermatol Venerol; 2023 Jun; 158(3):249-254. PubMed ID: 37278501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Musculoskeletal Symptoms in Patients with Psoriasis and Predictors Associated with the Development of Psoriatic Arthritis: Retrospective Analysis of a US Claims Database.
    Merola JF; Patil D; Egana A; Steffens A; Webb NS; Gottlieb AB
    Dermatol Ther (Heidelb); 2023 Nov; 13(11):2635-2648. PubMed ID: 37726542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
    Lebwohl M; Langley RG; Paul C; Puíg L; Reich K; van de Kerkhof P; Wu HL; Richter S; Jardon S; Gisondi P
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):61-78. PubMed ID: 34704231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and prevalence of psoriatic arthritis in patients with psoriasis stratified by psoriasis disease severity: Retrospective analysis of an electronic health records database in the United States.
    Merola JF; Tian H; Patil D; Richardson C; Scott A; Chen YH; Kim N; Hur P; Armstrong AW
    J Am Acad Dermatol; 2022 Apr; 86(4):748-757. PubMed ID: 34547358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K; Lawton M; Robertson N; Tremlett H; Zhu F; Harding K; Oger J; Ben-Shlomo Y
    Health Technol Assess; 2016 Oct; 20(81):1-48. PubMed ID: 27817792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocrelizumab in highly disabled progressive multiple sclerosis patients.
    Houtchens M; Howard D
    Mult Scler Relat Disord; 2024 Feb; 82():105345. PubMed ID: 38181693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased incidence and prevalence of psoriasis in multiple sclerosis.
    Marrie RA; Patten SB; Tremlett H; Wolfson C; Leung S; Fisk JD
    Mult Scler Relat Disord; 2017 Apr; 13():81-86. PubMed ID: 28427708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychosocial stress affects the change of mental distress under dermatological treatment-A prospective cohort study in patients with psoriasis.
    Wintermann GB; Bierling AL; Peters EMJ; Abraham S; Beissert S; Weidner K
    Stress Health; 2024 Feb; 40(1):e3263. PubMed ID: 37243509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab.
    Berkovich R; Yakupova A; Eskenazi J; Carlson NG; Steinman L
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33589543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low levels of emotional awareness predict a better response to dermatological treatment in patients with psoriasis.
    Consoli SM; Rolhion S; Martin C; Ruel K; Cambazard F; Pellet J; Misery L
    Dermatology; 2006; 212(2):128-36. PubMed ID: 16484819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.